Compounds > cabergoline
Page last updated: 2024-08-23

cabergoline and everolimus

cabergoline has been researched along with everolimus in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ambrosio, MR; Buratto, M; Degli Uberti, EC; Filieri, C; Lapparelli, M; Minoia, M; Scanarini, M; Tagliati, F; Zatelli, MC1
Colao, A; De Martino, MC; Faggiano, A; Franco, R; Kaltsas, GA; Marino, FZ; Napolitano, M; Negri, M; Patalano, R; Pivonello, C; Pivonello, R; Rocco, G; Rousaki, P; Sarnataro, M; Sciammarella, C1
Bergsneider, M; Heaney, AP; Sergey, M; Wang, MB; Way, JS; Yong, WH; Zhang, D; Zhang, X1

Reviews

1 review(s) available for cabergoline and everolimus

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for cabergoline and everolimus

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:2

    Topics: Adenoma; Aged; Apoptosis; Cabergoline; Cell Line, Tumor; Cell Survival; Ergolines; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Pituitary Neoplasms; Receptors, Somatostatin; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Somatostatin; Vascular Endothelial Growth Factor A

2010
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
    Endocrine, 2017, Volume: 56, Issue:3

    Topics: Antineoplastic Agents; Cabergoline; Carcinoid Tumor; Cell Line, Tumor; Cell Survival; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Everolimus; Humans; Lung Neoplasms; Octreotide; Receptors, Dopamine D2; Receptors, Somatostatin; Signal Transduction; Somatostatin; TOR Serine-Threonine Kinases

2017
Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.
    The Journal of clinical endocrinology and metabolism, 2019, 06-01, Volume: 104, Issue:6

    Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Everolimus; Humans; Hypophysectomy; Magnetic Resonance Imaging; Male; Mice; Off-Label Use; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Radiotherapy, Adjuvant; Reoperation; TOR Serine-Threonine Kinases; Treatment Outcome

2019